FERM domain containing 4AGenealiases: CCAFCA · FRMD4 · bA295P9.4
Q-omics provides the consensus-scored FRMD4A profile across patient tissues and cancer cell-line models. FRMD4A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FRMD4A is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, FRMD4A RNA expression shows 19,478 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, THCA, and UVM as cancer lineages where FRMD4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRMD4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRMD4A survival associations across molecular data types. FRMD4A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRMD4A RNA expression–survival associations across cancer types. High FRMD4A expression shows unfavorable associations in ACC, COAD and MESO, but favorable associations in HNSC, KIRC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FRMD4A RNA expression.
This table summarizes FRMD4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FRMD4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRMD4A shows lower tumor expression in THCA, LUAD, KICH, BRCA and UCEC and higher tumor expression in HNSC. The THCA box plot shows higher FRMD4A RNA expression in normal versus tumor tissue (log2 FC = −0.988, t-test p < 0.001).
This table shows molecular features associated with FRMD4A in patient tissues and cancer cell lines. In patient samples, FRMD4A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FRMD4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
